Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 901–1,000 of 1,017
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells
Kim, J. W., Berrios, C. J., Kim, M., Schade, A. E., Adelmant, G., Yeerna, H., Damato, E., Iniguez, A. B., Swanson, S. K., Florens, L. A., et al. (2020) · eLife · doi:10.7554/elife.53003 · Cited by 58
Benedict, B., van Schie, J. J. M., Oostra, A. B., Balk, J. A., Wolthuis, R. M. F., Riele, H. T., & de Lange, J. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.01.024 · Cited by 59
Epiregulin as a therapeutic target in non-small-cell lung cancer
Sunaga, N., & Kaira, K. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s60427 · Cited by 66
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer
Cai, H., Chew, S. K., Li, C., Tsai, M. K., Andrejka, L., Murray, C. W., Hughes, N. W., Shuldiner, E. G., Ashkin, E. L., Tang, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1325 · Cited by 54
Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium
Yamaguchi, M., Nakaoka, H., Suda, K., Yoshihara, K., Ishiguro, T., Yachida, N., Saito, K., Ueda, H., Sugino, K., Mori, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28568-2 · Cited by 54
Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad
Sparaneo, A., Fabrizio, F. P., & Muscarella, L. A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7316492 · Cited by 56
“Finally, frequent cooccurring mutationsNFE2L2, KEAP1, andNOTCH1 in a study on more than four thousand human cancers support the notion that the outcome from aberrant Nrf2–Notch crosstalk by mutations in these genes might specifically enhance tumorigenesis and progression to cancer [142].”
BackgroundSPOP suppresses prostate cancer through regulation of CYCLIN E1 stability
Ju, L., Zhu, Y., Long, Q., Li, X., Lin, X., Tang, S., Yin, L., Xiao, Y., Wang, X., Li, L., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0198-0 · Cited by 62
Towards quantitative and multiplexed in vivo functional cancer genomics
Winters, I. P., Murray, C. W., & Winslow, M. M. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0053-7 · Cited by 56
Arruda, N. L., Carico, Z. M., Justice, M., Liu, Y. F., Zhou, J., Stefan, H. C., & Dowen, J. M. (2020) · Epigenetics & Chromatin · doi:10.1186/s13072-020-00353-9 · Cited by 59
Fixing the GAP: The role of RhoGAPs in cancer
Kreider-Letterman, G., Carr, N. M., & García‐Mata, R. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151209 · Cited by 58
How to read a next-generation sequencing report—what oncologists need to know
Schmid, S., Jochum, W., Padberg, B., Demmer, I., Mertz, K. D., Joerger, M., Britschgi, C., Matter, M. S., Rothschild, S. I., & Omlin, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100570 · Cited by 62
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Kong, L., Meng, F., Zhou, P., Ge, R., Geng, X., Yang, Z., Guo, L., Zhang, L., Wang, J., Ma, J., et al. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.05.017 · Cited by 57
Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology
Wang, Y., Rozen, V., Zhao, Y., & Wang, Z. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101430 · Cited by 76
Mutant p53 and mTOR/PKM2 regulation in cancer cells
Dando, I., Cordani, M., & Donadelli, M. (2016) · IUBMB Life · doi:10.1002/iub.1534 · Cited by 57
Gulbahce, N., Magbanua, M. J. M., Chin, R. G., Agarwal, M. R., Luo, X., Liu, J., Hayden, D. M., Mao, Q., Ciotlos, S., Li, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0688 · Cited by 57
New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis
Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 64
Lee, K.-H., Hwang, H., Noh, H. J., Shin, T.-J., & Cho, J. (2019) · Cancers · doi:10.3390/cancers11122006 · Cited by 55
Mészáros, B., Hajdu-Soltész, B., Zeke, A., & Dosztányi, Z. (2021) · Biomolecules · doi:10.3390/biom11030381 · Cited by 52
Coexpression patterns define epigenetic regulators associated with neurological dysfunction
Boukas, L., Havrilla, J. M., Hickey, P. F., Quinlan, A. R., Bjornsson, H. T., & Hansen, K. D. (2019) · Genome Research · doi:10.1101/gr.239442.118 · Cited by 53
“Regarding associations with cancer, we first identified EM genes potentially functioning as cancer drivers using: 1) a list of 260 significantly mutated cancer genes, derived from data spanning 21 tumor types (Lawrence et al., 2014), and 2) genes that were predicted to be drivers by at least one of the top 3 performin…”
MethodBolli, N., Manes, N., McKerrell, T., Chi, J., Park, N., Gundem, G., Quail, M. A., Sathiaseelan, V., Herman, B., Crawley, C. R., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113381 · Cited by 62
Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress
Liao, Y., Chen, C.-H., Xiao, T., Avalos, B. D. L. P., Dray, E. V., Cai, C., Gao, S., Shah, N., Zhang, Z., Feit, A. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105898119 · Cited by 55
Hugaboom, M. B., Wirth, L. V., Street, K., Ruthen, N. G., Jegede, O. A., Schindler, N. R., Shah, V., Zaemes, J. P., Ahmar, N. E., Matar, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0991 · Cited by 63
A highly recurrent RPS27 5'UTR mutation in melanoma
Dutton-Regester, K., Gartner, J. J., Emmanuel, R., Qutob, N., Davies, M. A., Gershenwald, J. E., Robinson, W., Robinson, S., Rosenberg, S. A., Scolyer, R. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2048 · Cited by 52
Dietz, S., Schirmer, U. B., Mercé, C., von Bubnoff, N. C. C., Dahl, E., Meister, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161012 · Cited by 56
Topology and structure of an engineered human cohesin complex bound to Pds5B
Hons, M. T., Huis in ‘t Veld, P. J., Kaesler, J., Rombaut, P., Schleiffer, A., Herzog, F., Stark, H., & Peters, J.-M. (2016) · Nature Communications · doi:10.1038/ncomms12523 · Cited by 52
Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance
Du, P., Huang, P., Huang, X., Li, X., Feng, Z., Li, F., Liang, S., Song, Y., Stenvang, J., Brünner, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14909-5 · Cited by 54
Halani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., et al. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0067-9 · Cited by 50
Oršolić, I., Bursać, S., Jurada, D., Hofman, I. D., Dembić, Z., Bártek, J., Mihalek, I., & Volarević, S. (2020) · Oncogene · doi:10.1038/s41388-020-1231-6 · Cited by 55
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Cabrera‐Andrade, A., Barigye, S. J., Munteanu, C. R., González‐Díaz, H., Pazos, A., Pérez‐Castillo, Y., & Tejera, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-62279-2 · Cited by 60
He, F., Chen, Z., Deng, W., Zhan, T., Huang, X., Zheng, Y., & Yang, H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107789 · Cited by 54
The oncogenic fusion landscape in pediatric CNS neoplasms
Roosen, M. M., Odé, Z., Bunt, J., & Kool, M. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02405-8 · Cited by 55
Role of epigenetics in lung cancer heterogeneity and clinical implication
Dong, N., Shi, L., Wang, D. C., Chen, C., & Wang, X. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.029 · Cited by 53
Mota, A., Colás, E., García‐Sanz, P., Campoy, I., Rojo‐Sebastián, A., Gatius, S., García, Á., Chiva, L. M., Alonso, S., Gil‐Moreno, A., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.143 · Cited by 68
Martínez‐Cardús, A., Morán, S., Musulén, E., Moutinho, C., Manzano, J. L., Martinez‐Balibrea, E., Tierno, M., Élez, E., Landolfi, S., Lorden, P., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.001 · Cited by 52
Ivanov, A. A., Revennaugh, B., Rusnak, L., González-Pecchi, V., Mo, X., Johns, M. A., Du, Y., Cooper, L., Moreno, C. S., Khuri, F. R., et al. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx743 · Cited by 53
Dzobo, K., Senthebane, D. A., Thomford, N. E., Rowe, A., Dandara, C., & Parker, M. I. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0174 · Cited by 55
HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia–Lymphoma
Yamagishi, M., Fujikawa, D., Watanabe, T., & Uchimaru, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01686 · Cited by 56
p190RhoGAPs, the ARHGAP35- and ARHGAP5-Encoded Proteins, in Health and Disease
Héraud, C., Pinault, M., Lagrée, V., & Moreau, V. (2019) · Cells · doi:10.3390/cells8040351 · Cited by 59
The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics
Zhang, S., O'Regan, R. M., & Xu, W. (2019) · Cancer · doi:10.1002/cncr.32672 · Cited by 60
The Multifactorial Role of PARP-1 in Tumor Microenvironment
Martí, J. M., Fernández‐Cortés, M., Serrano-Sáenz, S., Zamudio-Martínez, E., Delgado‐Bellido, D., García-Díaz, Á., & Oliver, F. J. (2020) · Cancers · doi:10.3390/cancers12030739 · Cited by 60
Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0973 · Cited by 50
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Ghazani, A. A., Oliver, N. M., Pierre, J. P. S., Garofalo, A., Rainville, I. R., Hiller, E. H., Treacy, D. J., Rojas‐Rudilla, V., Wood, S., Bair, E. F., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.191 · Cited by 58
Self-citationLee, K., Jeong, H., Lee, S., & Jeong, W. (2019) · Scientific Reports · doi:10.1038/s41598-019-53034-3 · Cited by 52
Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers
Arcella, A., Limanaqi, F., Ferese, R., Biagioni, F., Oliva, M. A., Storto, M., Fanelli, M., Gambardella, S., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020685 · Cited by 53
Karim, S., Burzangi, A. S., Ahmad, A., Siddiqui, N. A., Ibrahim, I. M., Sharma, P., Abualsunun, W. A., & Gabr, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042305 · Cited by 56
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era
Martin, S. D., Coukos, G., Holt, R. A., & Nelson, B. H. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv382 · Cited by 57
ccmGDB: a database for cancer cell metabolism genes
Kim, P., Cheng, F., Zhao, J., & Zhao, Z. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1128 · Cited by 66
Vinayanuwattikun, C., Calvez‐Kelm, F. L., Abedi‐Ardekani, B., Zaridze, D. G., Mukeria, A., Voegele, C., Vallée, M., Purnomosari, D., Forey, N., Durand, G., et al. (2016) · Scientific Reports · doi:10.1038/srep31628 · Cited by 53
Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma
Kancherla, V., Abdullazade, S., Matter, M. S., Lanzafame, M., Quagliata, L., Roma, G., Hoshida, Y., Terracciano, L., Ng, C. K. Y., & Piscuoglio, S. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00002 · Cited by 56
Systematic characterization of pan‐cancer mutation clusters
Buljan, M., Blattmann, P., Aebersold, R. H., & Boutros, M. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177974 · Cited by 50
“Cancer genome sequencing has had a major role in mapping cellular pathways leading to tumorigenesis (Lawrence et al , 2014; Leiserson et al , 2015) and in elucidating diverse molecular mechanisms that can drive oncogenic transformation (Alexandrov et al , 2013) and drug resistance (Garraway &…”
Preclinical models for precision oncology
Ibarrola‐Villava, M., Cervantes, A. M. R., & Bardelli, A. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.004 · Cited by 58
Song, J., Peng, W., & Wang, F. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2847-9 · Cited by 66
Guardia, G. D. A., Corrêa, B., Araujo, P. R. D., Qiao, M., Burns, S., Penalva, L. O. F., & Galante, P. A. F. (2020) · npj Genomic Medicine · doi:10.1038/s41525-019-0108-5 · Cited by 54
Cohesin mutations in myeloid malignancies
Jann, J.-C., & Tóthová, Z. (2021) · Blood · doi:10.1182/blood.2019004259 · Cited by 55
RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism
Wang, W., Shi, B., Cong, R., Hao, M., Peng, Y., Yang, H., Song, J., Feng, D., Zhang, N., & Li, D. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01162-7 · Cited by 53
Enhancer alterations in cancer: a source for a cell identity crisis
Kron, K. J., Bailey, S. D., & Lupien, M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0077-3 · Cited by 68
Kovar, H., Amatruda, J. F., Brunet, E., Burdach, S. E. G., Cidre‐Aranaz, F., de Álava, E., Dirksen, U., van der Ent, W., Grohar, P. J., Grünewald, T. G. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6937 · Cited by 57
Targeted Therapy for Cancer in the Genomic Era
Afghahi, A., & Sledge, G. W. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000135 · Cited by 55
DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers
Wang, D., Qian, X., Rajaram, M., Durkin, M. E., & Lowy, D. R. (2016) · Oncotarget · doi:10.18632/oncotarget.9266 · Cited by 55
Alldredge, J. K., & Eskander, R. N. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0052-y · Cited by 60
Precision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 52
Genomics-Guided Immunotherapy for Precision Medicine in Cancer
Mukherjee, S. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2758 · Cited by 58
Next-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
Menon, V., & Brash, D. E. (2023) · Mutation Research - Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108471 · Cited by 48
Tissue-based next generation sequencing: application in a universal healthcare system
Hynes, S. O., Pang, B., James, J. A., Maxwell, P., & Salto‐Tellez, M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.452 · Cited by 51
Spatial organization of PI3K-PI(3,4,5)P3-AKT signaling by focal adhesions
Wang, J., An, Z., Wu, Z., Zhou, W., Sun, P., Wu, P., Dang, S., Xue, R., Bai, X., Du, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.10.010 · Cited by 51
Single-Cell Genetic Analysis Using Automated Microfluidics to Resolve Somatic Mosaicism
Szulwach, K. E., Chen, P., Wang, X., Wang, J., Weaver, L. S., Gonzales, M. L., Sun, G., Unger, M., & Ramakrishnan, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135007 · Cited by 48
Sakr, R. A., Schizas, M., Carniello, J. V. S., Ng, C. K. Y., Piscuoglio, S., Giri, D. D., de Andrade, V. P., Brot, M. D., Lim, R. S., Towers, R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.001 · Cited by 50
Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis
Siraj, A. K., Masoodi, T., Bu, R., Beg, S., Al-Sobhi, S. S., Al‐Dayel, F., Aldawish, M., Alkuraya, F. S., & Al-Kuraya, K. S. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.04.014 · Cited by 48
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 62
Oba, D., Inoue, S., Miyagawa‐Tomita, S., Nakashima, Y., Niihori, T., Yamaguchi, S., Matsubara, Y., & Aoki, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.029 · Cited by 48
Micheel, C., Sweeney, S. M., Lenoue-Newton, M. L., André, F., Bedard, P. L., Guinney, J., Meijer, G. A., Rollins, B. J., Sawyers, C. L., Schultz, N. D., et al. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00083 · Cited by 47
MaxMIF: A New Method for Identifying Cancer Driver Genes through Effective Data Integration
Hou, Y., Gao, B., Li, G., & Su, Z. (2018) · Advanced Science · doi:10.1002/advs.201800640 · Cited by 55
Ortiz, M. V., Kobos, R., Walsh, M. F., Slotkin, E. K., Roberts, S. S., Berger, M. F., Hameed, M., Solit, D. B., Ladanyi, M., Shukla, N. N., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26002 · Cited by 49
Kyrochristos, I. D., & Roukos, D. H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101894 · Cited by 54
QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer
Wang, J.-Z., Fu, X., Fang, Z., Liu, H., Zong, F.-Y., Zhu, H. M., Yu, Y.-F., Zhang, X.-Y., Wang, S.-F., Huang, Y., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa063 · Cited by 57
“By analyzing somatic mutation databases, we identified several QKI mutations in bladder, colon, esophageal adenocarcinoma, endometrial, glioblastoma, and lung adenocarcinoma cancers (Lawrence et al., 2014 ).”
Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients
García, M. E. G., Kirsch, D. G., & Reitman, Z. J. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.09.008 · Cited by 55
Kim, S., Park, J. W., Seo, H., Kim, M. J., Park, J., Kim, G., Lee, J. O., Shin, Y., Bae, J. M., Koo, B., et al. (2021) · Advanced Science · doi:10.1002/advs.202103360 · Cited by 52
Nevedomskaya, E., & Haendler, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116281 · Cited by 53
Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
Wang, M., Banik, I., Shain, A. H., Yeh, I., & Bastian, B. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01068-0 · Cited by 50
Emerging role of different DNA methyltransferases in the pathogenesis of cancer
Liu, P., Yang, F., Zhang, L., Hu, Y., Chen, B., Wang, J., Su, L., Wu, M., & Chen, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958146 · Cited by 61
“The PI3K/AKT signaling pathway is the most frequently activated pathway in cancers and works for disconnecting the control of cell growth, survival, and metabolism from exogenous growth stimuli (Lawrence et al., 2014).”
BackgroundRolfs, F., Huber, M., Kuehne, A., Kramer, S., Haertel, E., Muzumdar, S., Wagner, J., Tanner, Y., Böhm, F., Smola, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0614 · Cited by 47
Silent Mutations Make Some Noise
Zheng, S., Kim, H., & Verhaak, R. G. W. (2014) · Cell · doi:10.1016/j.cell.2014.02.037 · Cited by 49
“Recent saturation analysis suggested that up to 5,000 cancer-normal pairs are needed to comprehensively characterize the long distribution tail of less frequently mutated cancer drivers (Lawrence et al., 2014).”
BackgroundMEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations
Hua, X., Hyland, P. L., Huang, J. L., Song, L., Zhu, B., Caporaso, N. E., Landi, M. T., Chatterjee, N., & Shi, J. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.12.021 · Cited by 46
Stern, A. M., Schurdak, M. E., Bahar, İ., Berg, J. M., & Taylor, D. L. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116635818 · Cited by 50
Shimoi, T., Hamada, A., Yamagishi, M., Hirai, M., Yoshida, M., Nishikawa, T., Sudo, K., Shimomura, A., Noguchi, E., Yunokawa, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13696 · Cited by 59
SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications
Fukumoto, T., Magno, E., & Zhang, R. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0368 · Cited by 49
Elman, J. S., Ni, T. K., Mengwasser, K. E., Jin, D. X., Wronski, A., Elledge, S. J., & Kuperwasser, C. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.060 · Cited by 52
“They are underpowered because of the relatively few tumors for many tumor types (Bailey et al., 2018; Lawrence et al., 2014; Liu et al., 2006; Merid et al., 2014; Tokheim et al., 2016).”
BackgroundMolecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma
Chen, C., Shi, C., Huang, X., Zheng, J., Zhu, Z., Li, Q., Qiu, S., Huang, Z., Zhuang, Z., Wu, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50171-7 · Cited by 66
Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs secondary primary tumor
Gleber‐Netto, F. O., Braakhuis, B. J. M., Triantafyllou, A. G., Takes, R. P., Kelner, N., Rodrigo, J. P., Strojan, P., Poorten, V. V., Rapidis, A. D., Rinaldo, A., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.04.016 · Cited by 46
PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Park, S., Kim, Y. S., Kim, D. Y., So, I., & Jeon, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.001 · Cited by 47
An Entropy-Based Method for Identifying Mutual Exclusive Driver Genes in Cancer
Song, J., Peng, W., & Wang, F. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2897931 · Cited by 55
“that is although a part of driver genes are mutated at high frequencies (>20%) most of cancer mutations occur at intermediate frequencies(2-20 percent)or lower than the expected [13].”
BackgroundBioactive cell penetrating peptides and proteins in cancer: a bright future ahead
Jauset, T., & Beaulieu, M.-È. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.014 · Cited by 48
Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer
Masoodi, T., Siraj, A. K., Siraj, S., Azam, S., Qadri, Z., Albalawy, W. N., Parvathareddy, S. K., Al-Sobhi, S. S., Al‐Dayel, F., Alkuraya, F. S., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0052 · Cited by 48
“Cancer genes were annotated based on previously published studies (40–42).”
Time for remodeling: SNF2-family DNA translocases in replication fork metabolism and human disease
Joseph, S. A., Taglialatela, A., Leuzzi, G., Huang, J., Cuella-Martin, R., & Ciccia, A. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102943 · Cited by 48
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 45
A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement
Zhang, Y., Chen, F., Donehower, L. A., Scheurer, M. E., & Creighton, C. J. (2021) · Nature Communications · doi:10.1038/s41467-021-21081-y · Cited by 51
Selective advantage of epigenetically disrupted cancer cells via phenotypic inertia
Loukas, I., Simeoni, F., Milan, M., Inglese, P., Patel, H., Goldstone, R., East, P., Strohbuecker, S., Mitter, R., Talsania, B., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.002 · Cited by 46
Identification of 33 candidate oncogenes by screening for base-specific mutations
Tuupanen, S., Hänninen, U. A., Kondelin, J., von Nandelstadh, P., Cajuso, T., Gylfe, A. E., Katainen, R., Tanskanen, T. J., Ristolainen, H., Böhm, J., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.429 · Cited by 48
“%) or low frequencies is far from complete (Lawrence et al, 2014).”
BackgroundNetCore: a network propagation approach using node coreness
Barel, G., & Herwig, R. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa639 · Cited by 59
“We applied NetCore to a pan-cancer somatic mutation data set (42).”
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.